ArticleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2019

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Hossein Borghaei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.